STOCK TITAN

Celanese Corp Del Stock Price, News & Analysis

CE NYSE

Welcome to our dedicated page for Celanese Del news (Ticker: CE), a resource for investors and traders seeking the latest updates and insights on Celanese Del stock.

Celanese Corp Del (CE) delivers essential chemical solutions and specialty materials powering industries from automotive to electronics. This dedicated news hub provides investors and professionals with timely updates on corporate developments, financial milestones, and technical innovations.

Access authoritative coverage of earnings announcements, strategic partnerships, and product advancements that shape Celanese's market leadership. Our curated collection features official press releases and third-party analysis of critical initiatives in polymer engineering, cellulose derivatives, and sustainable production methods.

Key updates include financial performance reports, manufacturing capacity expansions, and R&D breakthroughs in high-performance materials. Track the company's progress in addressing evolving demands across global markets while maintaining operational excellence in chemical engineering.

Bookmark this page for streamlined access to Celanese's latest business developments. Stay informed about the specialty materials sector through comprehensive coverage of CE's strategic positioning and industry impact.

Rhea-AI Summary

Celanese (NYSE: CE) has announced a partnership with Glaukos Corporation to supply its VitalDose® Drug Delivery Platform for the iDose® TR intraocular implant. This device aims to lower intraocular pressure in patients with glaucoma by providing continuous, long-duration therapy, addressing issues of patient non-adherence to topical medications. Glaukos submitted a New Drug Application for iDose TR in February 2023, pending FDA approval. The collaboration is aimed at enhancing patient treatment options in ophthalmology, leveraging the proven performance of Celanese's VitalDose technology, which has a solid history of controlled-release applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
Rhea-AI Summary

Celanese Corporation (NYSE: CE) has announced a collaboration with Alessa Therapeutics to develop a new oncology drug using Alessa's sustained localized drug delivery technology. The partnership aims to enhance treatment for oncology patients by reducing systemic side effects.

According to Alessa's Vice President, the collaboration has facilitated the rapid development of their drug candidate, with plans to advance to human studies later this year. Celanese emphasized its commitment to improving therapeutic outcomes through innovative drug delivery solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
none
-
Rhea-AI Summary

Celanese Corporation (NYSE: CE), a leader in specialty materials, announced price hikes for Hytrel® TPC resins, set to take effect on March 15, 2023. The increases include 0.45 EUR/kg in the EMEA region and 0.5 USD/kg in both Asia Pacific and the Americas. Individual grades may experience greater hikes as per contract terms. Celanese, headquartered in Dallas, reported $9.7 billion in net sales for 2022 and employs around 13,000 people globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
Rhea-AI Summary

Celanese Corporation (NYSE: CE) reported record GAAP diluted EPS of $17.41 and adjusted EPS of $15.88 for 2022, achieving net sales of $9.7 billion, up 13% from 2021. Despite significant raw material and energy cost inflation of over $1.2 billion, the company offset these pressures through pricing increases. The acquisition of DuPont's Mobility & Materials business significantly contributed to Celanese's performance. In Q4 2022, GAAP diluted EPS was $7.03, with adjusted EPS of $1.44, reflecting challenges from destocking and demand fluctuations, particularly in Asia. The company anticipates improved earnings in Q1 2023, projecting adjusted EPS between $1.50 to $1.75.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
-
Rhea-AI Summary

Celanese Corporation (NYSE: CE) announced a strategic partnership expansion with Mitsui & Co., Ltd., including a new Food Ingredients joint venture (JV) and an extension of the Fairway Methanol LLC JV. Celanese will contribute its Food Ingredients business to the JV, retaining a 30% stake, while Mitsui will own 70%. The Food Ingredients segment generated $170 million in 2022 net sales and $45-$50 million in EBITDA. The Fairway Methanol JV will now operate through 2045 and is set for an expansion to 1.62 million metric tons, utilizing recycled CO2 in production. The expected closure for these transactions is Q3 2023, with proceeds aimed at debt reduction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
Rhea-AI Summary

Celanese Corporation (NYSE: CE) announced the successful completion of an ultra-low capital project to boost ethylene vinyl acetate (EVA) capacity at its Edmonton, Alberta facility. This expansion will provide a 35% increase in EVA capacity starting Q1 2023, contributing approximately $10 million per year in additional operating EBITDA. The demand for EVA, particularly in solar applications, is projected to grow at a double-digit compounded annual rate through 2028. This strategic move strengthens Celanese's position in the acetyls market, enhancing its capability to meet rising demand across various high-value applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
none
Rhea-AI Summary

Celanese Corporation (NYSE: CE) has announced a collaboration with Johns Hopkins University Department of Ophthalmology to study sustained drug delivery to the eye's suprachoroidal space. This approach aims to reduce the frequency of ocular injections for retinal disorders. Utilizing the VitalDose® Drug Delivery Platform, the bioinert implant promises over six months of continuous therapeutic delivery, enhancing patient compliance. The Celanese Development & Feasibility Lab will conduct parts of the research, supporting the development of long-acting drug delivery systems.

Celanese remains committed to improving healthcare solutions in ophthalmology and other fields.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
-
Rhea-AI Summary

Celanese Corporation (NYSE: CE) declared a quarterly cash dividend of $0.70 per share on common stock, set to be paid on March 7, 2023. Stockholders of record as of February 21, 2023 will receive this dividend. Celanese is a global leader in specialty materials and chemicals, leveraging advanced chemistry and technology to serve various industries. In 2021, the company reported net sales of $8.5 billion and employs approximately 13,000 personnel globally. For further details on Celanese's operations and product offerings, visit www.celanese.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
dividends
-
Rhea-AI Summary

Celanese Corporation (NYSE: CE) has launched a new range of sustainable Acetyl Chain materials known as ECO-B, which feature mass balance bio-content. This initiative aims to support customers in reducing CO2 emissions and achieving sustainability goals. ECO-B products, including Emulsion Polymers and EVA Polymers, provide a chemical identity identical to standard offerings while promoting renewable content. The new products aim to help industries like building and construction, adhesives, and packaging. Sustainable content in ECO-B products can range from 10% to 100%, depending on specific items.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
none
Rhea-AI Summary

Celanese Corporation (NYSE: CE) will host a conference call on February 24, 2023, to discuss its fourth quarter 2022 results. The call is delayed due to the ongoing integration of the Mobility & Materials acquisition. Investors can access the call via webcast or by phone. The earnings press release will be distributed on February 23, 2023, post-market close. A replay will be accessible from 12:00 p.m. Eastern time on February 24 until March 10, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
conferences earnings

FAQ

What is the current stock price of Celanese Del (CE)?

The current stock price of Celanese Del (CE) is $48.73 as of September 5, 2025.

What is the market cap of Celanese Del (CE)?

The market cap of Celanese Del (CE) is approximately 5.1B.
Celanese Corp Del

NYSE:CE

CE Rankings

CE Stock Data

5.08B
109.02M
0.43%
107.82%
5.9%
Chemicals
Plastic Material, Synth Resin/rubber, Cellulos (no Glass)
Link
United States
IRVING